Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

被引：62
|
作者：
Gadgeel, Shirish M.
Stevenson, James
Langer, Corey J.
Gandhi, Leena
Borghaei, Hossein
Patnaik, Amita
Villaruz, Liza Cosca
Gubens, Matthew A.
Hauke, Ralph J.
Yang, James Chih-Hsin
Sequist, Lecia V.
Bachman, Robert D.
Ge, Joy Yang
Raftopoulos, Harry
Papadimitrakopoulou, Vassiliki
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[6] South Texas Accelerated Res Theraput, San Antonio, TX USA
[7] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Nebraska Canc Specialists, Omaha, NE USA
[10] Natl Taiwan Univ Hosp, Taipei, Taiwan
[11] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[12] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[13] Harvard Med Sch, Boston, MA 02115 USA
[14] Merck & Co Inc, Kenilworth, NJ USA
[15] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9016
引用
收藏
页数：3
相关论文
共 50 条
  • [41] KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
    Gandhi, Leena
    Rodgriguez-Abreu, Delvys
    Gadgeel, Shirish
    Esteban, Emilio
    Felip, Enriqueta
    De Angelis, Flavia
    Domine, Manuel
    Clingan, Philip
    Hochmair, Maximilian J.
    Powell, Steven
    Cheng, Susanna Yee-Shan
    Bischoff, Helge G.
    Peled, Nir
    Grossi, Francesco
    Jennens, Ross R.
    Reck, Martin
    Hui, Rina
    Garon, Edward B.
    Boyer, Michael
    Rubio-Viqueira, Belen
    Novello, Silvia
    Kurata, Takayasu
    Gray, Jhanelle E.
    Vida, John J.
    Wei, Ziwen
    Yang, Jing
    Raftopoulos, Harry
    Pietanza, M. Catherine
    Garassino, Marina C.
    CANCER RESEARCH, 2018, 78 (13)
  • [42] First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407
    Robinson, A. G.
    Vicente, D.
    Tafreshi, A.
    Parra, H. Soto
    Mazieres, J.
    Cicin, I.
    Medgyasszay, B.
    Rodriguez-Cid, J.
    Okamoto, I.
    Lee, S.
    Ramlau, R.
    Vladimirov, V.
    Cheng, Y.
    Halmos, B.
    Liu, C-C.
    Schwarzenberger, P.
    Piperdi, B.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S748 - S749
  • [43] Pembrolizumab plus Chemotherapie als Erstlinientherapie beim fortgeschrittenen Ösophaguskarzinom (KEYNOTE-590)Pembrolizumab plus chemotherapy as first-line treatment in advanced oesophageal cancer (KEYNOTE-590)
    Milan Hartmann
    Thomas Zander
    Hakan Alakus
    Der Onkologe, 2022, 28 (5): : 436 - 437
  • [44] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study.
    Shah, Manish A.
    Sun, Jong-Mu
    Shen, Lin
    Kato, Ken
    Enzinger, Peter C.
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Li, Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chul
    Mansoor, Wasat
    Li, Shau-Hsuan
    Sunpaweravong, Patrapim
    Maqueda, Maria Alsina
    Buchschacher, Gary L.
    Wu, Jimin
    Shah, Sukrut
    Bhagia, Pooja
    Metges, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 250 - 250
  • [45] Niraparib plus Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study
    Ramalingam, S.
    Arora, S.
    Neibauer, M. Whipple
    Zhou, J.
    Hazard, S.
    Frenkl, T.
    Stojadinovic, A.
    Peters, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S653 - S654
  • [46] Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.
    Morales-Barrera, Rafael
    Powles, Thomas
    Ozguroglu, Mustafa
    Csoszi, Tibor
    Loriot, Yohann
    Flechon, Aude
    Matsubara, Nobuaki
    Rodriguez-Vida, Alejo
    Geczi, Lajos
    Cheng, Susanna Y.
    Fradet, Yves
    Oudard, Stephane
    Gunduz, Seyda
    Ma, Junshui
    Rajasagi, Mohini
    Vajdi, Amir
    Cristescu, Razvan
    Imai, Kentaro
    Moreno, Blanca Homet
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [47] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
    Chen, Pingyu
    Wang, Xintian
    Zhu, Shengwen
    Li, Hongchao
    Rui, Mingjun
    Wang, Yingcheng
    Sun, Haikui
    Ma, Aixia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [48] PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE (SER) TO FRONT-LINE CHEMOTHERAPY (KEYNOTE-667)
    Vinti, Luciana
    Daw, Stephen
    Alvarez, Constantino Sabado
    Fagioli, Franca
    Beishuizen, Auke
    Michel, Gerald
    Moleti, Maria
    Cepelova, Michaela
    Thorwarth, Anne
    Rigaud, Charlotte
    De Sabando, Diego Plaza Lopez
    Landman-Parker, Judith
    Shen, Juan
    Pillai, Pallavi
    Marinello, Patricia
    Mauz-Koerholz, Christine
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S29 - S30
  • [49] 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer
    Borghaei, Hossein
    Langer, Corey J.
    Gadgeel, Shirish
    Papadimitrakopoulou, Vassiliki A.
    Patnaik, Amita
    Powell, Steven F.
    Gentzler, Ryan D.
    Martins, Renato G.
    Stevenson, James P.
    Jalal, Shadia I.
    Panwalkar, Amit
    Yang, James Chih-Hsin
    Gubens, Matthew
    Sequist, Lecia V.
    Awad, Mark M.
    Fiore, Joseph
    Saraf, Sanatan
    Keller, Steven M.
    Gandhi, Leena
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) : 124 - 129
  • [50] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
    Schmid, Peter
    Cortes, Javier
    Bergh, Jonas C. S.
    Pusztai, Lajos
    Denkert, Carsten
    Verma, Sunil
    McArthur, Heather L.
    Kummel, Sherko
    Ding, Yu
    Karantza, Vassiliki
    Dang, Thao
    Dent, Rebecca Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345